MR 409

MR 409 is a selected growth hormone-releasing hormone (GHRH) agonist. MR 409 has remarkable neuroprotective effects through enhancing endogenous neurogenesis in cerebral ischemic mice. MR 409 also inhibits the in vivo growth of lung cancer[1][2][3][4].

Product Specifications

CAS Number

[1445155-39-4]

UNSPSC

12352209

Target

GHSR

Type

Peptides

Related Pathways

GPCR/G Protein

Applications

Cancer-programmed cell death

Field of Research

Cancer; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/mr-409.html

Purity

99.51

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : ≥ 50 mg/mL

Smiles

[C@@H](CC1=CC=CC=C1)(NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](NC([C@H](CC2=CC=C(O)C=C2)NC)=O)C)=O)CC(O)=O)=O)C)=O)[C@H](CC)C)=O)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CC3=CC=C(O)C=C3)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CCCNC(=N)N)C(NC)=O)=O)CC(O)=O)=O)CCCC)=O)[C@H](CC)C)=O)CC(O)=O)=O)CCC(N)=O)=O)CC(C)C)=O)CC(C)C)=O)CCCN)=O)CCCNC(=N)N)=O)C)=O)CO)=O)CC(C)C)=O)CCC(N)=O)=O)CC)=O)CC(C)C)=O)[C@H](C)C)=O)CCCN)=O)CCCNC(=N)N)=O)=O)CO)=O)CC(N)=O)=O)[C@@H](C)O)=O

Molecular Formula

C153H252N44O43

Molecular Weight

3395.91

References & Citations

[1]Rosemeire M Kanashiro-Takeuchi, et al. New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor. Oncotarget. 2015;6 (12) :9728-39.|[2]Mohammad A Uddin, et al. GHRH antagonists support lung endothelial barrier function. Tissue Barriers. 2019;7 (4) :1669989.|[3]Lucia Recinella, et al. Protective effects of growth hormone-releasing hormone analogs in DSS-induced colitis in mice. Sci Rep. 2021 Jan 28;11 (1) :2530.|[4]Yueyang Liu, et al. Agonistic analog of growth hormone-releasing hormone promotes neurofunctional recovery and neural regeneration in ischemic stroke. Proc Natl Acad Sci U S A. 2021 Nov 23;118 (47) :e2109600118.